Your browser doesn't support javascript.
loading
Nanobioactive Blood-Derived Shear-Thinning Biomaterial for Tissue Engineering Applications.
Gangrade, Ankit; Zehtabi, Fatemeh; Rashad, Ahmad; Haghniaz, Reihaneh; Falcone, Natashya; Mandal, Kalpana; Khosravi, Safoora; Deka, Sangeeta; Yamauchi, Alana; Voskanian, Leon; Kim, Han-Jun; Ermis, Menekse; Khademhosseini, Ali; de Barros, Natan Roberto.
Affiliation
  • Gangrade A; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Zehtabi F; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Rashad A; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Haghniaz R; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Falcone N; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Mandal K; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Khosravi S; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Deka S; Indian Institute of Technology Guwahati, Assam, India, Pin-781039.
  • Yamauchi A; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Voskanian L; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Kim HJ; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
  • Ermis M; College of Pharmacy, Korea University, 30019, Republic of Korea.
  • Khademhosseini A; Vellore Institute of Technology (VIT), Vellore, 632014, India.
  • de Barros NR; Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
Appl Mater Today ; 382024 Jun.
Article in En | MEDLINE | ID: mdl-39006868
ABSTRACT
The conventional technique for successful bone grafts, involving the use of a patients own tissue (autografts), is challenged by limited availability and donor site morbidity. While allografts and xenografts offer alternatives, they come with the risk of rejection. This underscores the pressing need for tailor-made artificial bone graft materials. In this context, injectable hydrogels are emerging as a promising solution for bone regeneration, especially in complex maxillofacial reconstruction cases. These hydrogels can seamlessly adapt to irregular shapes and conservatively fill defects. Our study introduces a shear-thinning biomaterial by blending silicate nanoplatelets (SNs) enriched with human blood-derived plasma rich in growth factors (PRGF) for personalized applications. Notably, our investigations unveil that injectable hydrogel formulations comprising 7.5% PRGF yield sustained protein and growth factor release, affording precise control over critical growth factors essential for tissue regeneration. Moreover, our hydrogel exhibits exceptional biocompatibility in vitro and in vivo and demonstrates hemostatic properties. The hydrogel also presents a robust angiogenic potential and an inherent capacity to promote bone differentiation, proven through Alizarin Red staining, gene expression, and immunostaining assessments of bone-related biomarkers. Given these impressive attributes, our hydrogel stands out as a leading candidate for maxillofacial bone regeneration application. Beyond this, our findings hold immense potential in revolutionizing the field of regenerative medicine, offering an influential platform for crafting precise and effective therapeutic strategies.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Appl Mater Today Year: 2024 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Appl Mater Today Year: 2024 Document type: Article Affiliation country: United States
...